Teva Pharmaceuticals, aU.S. chapter of Teva Pharmaceutical diligenceLtd.( NYSE and TASE TEVA), has reached an agreement with the Attorney General of Arkansas to settle the state’s price- fixing claims against Teva. Under the terms of the agreement, Teva will pay the state$931,000,and the state will dismiss all of its claims against Teva and its cells formerly payment has been made.
This is the fourth agreement of the price- fixing action that Teva has reached to date, having preliminarily settled with Mississippi, Louisiana, and Georgia.( Alabama also lately freely dismissed its claims against all defendants in the action, including Teva.) Teva is pleased to put these claims behind us, and we believe the modest agreement quantum — in each of the four agreements to date — reflects our position on the allegations against us, which we continue to deny. We remain focused on delivering high- quality drugs to the cases around the world who need them, while also working cooperatively with state controllers to resolve heritage action matters in the United States, including these cases as well as the opioids cases. We’re agitating agreements of the price- fixing action with fresh countries in an trouble to continue replicating these results.
Teva Pharmaceutical diligenceLtd.( NYSE and TASE TEVA) has been developing and producing drugs to ameliorate people’s lives for further than a century. We’re a global leader in general and specialty drugs with a portfolio conforming of over,500 products in nearly every remedial area. Around 200 million people around the world take a Teva drug every day, and are served by one of the largest and most complex force chains in the pharmaceutical assiduity. Along with our established presence in generics, we’ve significant innovative exploration and operations supporting our growing portfolio of specialty and biopharmaceutical products.